<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">nnp</journal-id><journal-title-group><journal-title xml:lang="en">Neurology, Neuropsychiatry, Psychosomatics</journal-title><trans-title-group xml:lang="ru"><trans-title>Неврология, нейропсихиатрия, психосоматика</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2074-2711</issn><issn pub-type="epub">2310-1342</issn><publisher><publisher-name>"IMA-Press", LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14412/2074-2711-2025-1-10-15</article-id><article-id custom-type="elpub" pub-id-type="custom">nnp-2443</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL INVESTIGATIONS AND METHODS</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ И МЕТОДИКИ</subject></subj-group></article-categories><title-group><article-title>Aggressive multiple sclerosis in the Republic of Bashkortostan</article-title><trans-title-group xml:lang="ru"><trans-title>Агрессивный рассеянный склероз в Республике Башкортостан</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0982-4324</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бахтиярова</surname><given-names>К. З.</given-names></name><name name-style="western" xml:lang="en"><surname>Bakhtiyarova</surname><given-names>K. Z.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Клара Закиевна Бахтиярова</p><p>450008, Уфа, ул. Ленина, 3</p></bio><bio xml:lang="en"><p>Klara Zakievna Bakhtiyarova</p><p>Ufa, 3, Lenina St., Ufa 450008</p></bio><email xlink:type="simple">bsmu-neuro@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7056-7895</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кузьмина</surname><given-names>У. Ш.</given-names></name><name name-style="western" xml:lang="en"><surname>Kuzmina</surname><given-names>U. Sh.</given-names></name></name-alternatives><bio xml:lang="ru"><p>450008, Уфа, ул. Ленина, 3</p></bio><bio xml:lang="en"><p>Ufa, 3, Lenina St., Ufa 450008</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1393-1122</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лютов</surname><given-names>О. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Lyutov</surname><given-names>O. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>450008, Уфа, ул. Ленина, 3</p></bio><bio xml:lang="en"><p>Ufa, 3, Lenina St., Ufa 450008</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0009-1064-6589</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Талипова</surname><given-names>И. Д.</given-names></name><name name-style="western" xml:lang="en"><surname>Talipova</surname><given-names>I. D.</given-names></name></name-alternatives><bio xml:lang="ru"><p>450008, Уфа, ул. Ленина, 3</p></bio><bio xml:lang="en"><p>Ufa, 3, Lenina St., Ufa 450008</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1409-6704</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ахметгалеева</surname><given-names>Н. Ф.</given-names></name><name name-style="western" xml:lang="en"><surname>Akhmetgaleeva</surname><given-names>N. F.</given-names></name></name-alternatives><bio xml:lang="ru"><p>450008, Уфа, ул. Ленина, 3</p></bio><bio xml:lang="en"><p>Ufa, 3, Lenina St., Ufa 450008</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4558-6119</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Галиуллин</surname><given-names>Т. Р.</given-names></name><name name-style="western" xml:lang="en"><surname>Galiullin</surname><given-names>T. R.</given-names></name></name-alternatives><bio xml:lang="ru"><p>450008, Уфа, ул. Ленина, 3</p></bio><bio xml:lang="en"><p>Ufa, 3, Lenina St., Ufa 450008</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1001-2024</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кутлубаев</surname><given-names>М. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Kutlubaev</surname><given-names>M. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>450008, Уфа, ул. Ленина, 3</p></bio><bio xml:lang="en"><p>Ufa, 3, Lenina St., Ufa 450008</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБОУ ВО «Башкирский государственный медицинский университет» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Bashkir State Medical University, Ministry of Health of Russia</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>16</day><month>02</month><year>2025</year></pub-date><volume>17</volume><issue>1</issue><fpage>10</fpage><lpage>15</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Bakhtiyarova K.Z., Kuzmina U.S., Lyutov O.V., Talipova I.D., Akhmetgaleeva N.F., Galiullin T.R., Kutlubaev M.A., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Бахтиярова К.З., Кузьмина У.Ш., Лютов О.В., Талипова И.Д., Ахметгалеева Н.Ф., Галиуллин Т.Р., Кутлубаев М.А.</copyright-holder><copyright-holder xml:lang="en">Bakhtiyarova K.Z., Kuzmina U.S., Lyutov O.V., Talipova I.D., Akhmetgaleeva N.F., Galiullin T.R., Kutlubaev M.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://nnp.ima-press.net/nnp/article/view/2443">https://nnp.ima-press.net/nnp/article/view/2443</self-uri><abstract><p>Treatment of patients with aggressive multiple sclerosis (MS) characterized by severe progression of disability within a short period of time is a complex task as there are no uniform criteria for determining such disease progression type and, accordingly, no optimal strategies for prescribing medication. Standardised criteria are also needed to assess prevalence in the general patient population and to plan medical and social care.</p><sec><title>Objective</title><p>Objective: to analyse clinical and demographic characteristics of patients with aggressive MS in the Republic of Bashkortostan (RB).</p></sec><sec><title>Material and methods</title><p>Material and methods. The study included 2670 patients registered in the Multiple Sclerosis Centre of the Republic of Bashkortostan. To determine the types of MS progression, criteria of the 2022 clinical guidelines for MS were used. When analysing the data on disability, the data from the control group, which consisted of MS patients without limitations in working capacity and disability, were also used.</p></sec><sec><title>Results</title><p>Results. Rapidly progressive MS (RPMS) and highly active MS (HAMS) were diagnosed in 8.9% of the total number of patients. Women predominated in both groups. In the group of patients with aggressive MS, the progression rate was significantly higher than in the HAMS group. Six percent of patients included in the registry became disabled (group II or I) within 5 years of the disease, and 10% within 10 years. These groups are characterized by a high rate of disease progression.</p></sec><sec><title>Conclusion</title><p>Conclusion. In the RB, RPMS and HAMS were diagnosed in 8.9% of patients, with a predominance of women.</p></sec></abstract><trans-abstract xml:lang="ru"><p>Лечение больных с агрессивным рассеянным склерозом (РС), характеризующимся резким прогрессированием инвалидности в течение короткого периода времени, представляется сложной задачей в связи с отсутствием единых критериев для установления данного типа течения заболевания и, соответственно, оптимальных стратегий для назначения препаратов. Единые критерии требуются также для оценки его распространенности в общей популяции больных и планирования медико-социальной помощи.</p><p>Цель исследования – анализ клинико-демографических характеристик пациентов с агрессивным РС в Республике Башкортостан (РБ).</p><sec><title>Материал и методы</title><p>Материал и методы. В исследование было включено 2670 больных, состоящих на учете в Центре рассеянного склероза РБ. Для определения типов течения РС использовали критерии из Клинических рекомендаций по РС за 2022 г. При анализе данных о нетрудоспособности использовали также данные контрольной группы, которую составили пациенты с РС, не имеющие ограничений трудоспособности и группы инвалидности.</p></sec><sec><title>Результаты</title><p>Результаты. Быстропрогрессирующий РС (БПРС) и высокоактивный РС (ВАРС) диагностирован у 8,9% от общего числа пациентов. В обеих группах преобладают женщины. В группе больных с агрессивным РС скорость прогрессирования значимо выше, чем в группе ВАРС. Инвалидами II или I группы за 5 лет заболевания стали 6% пациентов, включенных в регистр, а за 10 лет – 10%. Для данных групп характерна большая скорость прогрессирования заболевания.</p></sec><sec><title>Заключение</title><p>Заключение. В РБ БПРС и ВАРС диагностированы у 8,9% пациентов с преобладанием у женщин.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>рассеянный склероз</kwd><kwd>агрессивный рассеянный склероз</kwd><kwd>высокоактивный рассеянный склероз</kwd><kwd>инвалидность</kwd></kwd-group><kwd-group xml:lang="en"><kwd>multiple sclerosis</kwd><kwd>aggressive multiple sclerosis</kwd><kwd>highly active multiple sclerosis</kwd><kwd>disability</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Исследование не имело спонсорской поддержки</funding-statement><funding-statement xml:lang="en">The investigation has not been sponsored</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Koch-Henriksen N, Magyari M. Apparent changes in the epidemiology and severity of multiple sclerosis. Nat Rev Neurol. 2021 Nov;17(11):676-88. doi: 10.1038/s41582-021-00556-y. Epub 2021 Sep 28.</mixed-citation><mixed-citation xml:lang="en">Koch-Henriksen N, Magyari M. Apparent changes in the epidemiology and severity of multiple sclerosis. Nat Rev Neurol. 2021 Nov;17(11):676-88. doi: 10.1038/s41582-021-00556-y. Epub 2021 Sep 28.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Клинические рекомендации – Рассеянный склероз – 2022–2023–2024 (13.07.2022). Утверждены Минздравом РФ.</mixed-citation><mixed-citation xml:lang="en">Clinical guidelines – Multiple sclerosis – 2022–2023–2024 (13.07.2022). Approved by the Ministry of Health of the Russian Federation (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Correale J, Rush CA, Barboza A. Are highly active and aggressive multiple sclerosis the same entity? Front Neurol. 2023 Mar 3;14:1132170. doi: 10.3389/fneur.2023.1132170</mixed-citation><mixed-citation xml:lang="en">Correale J, Rush CA, Barboza A. Are highly active and aggressive multiple sclerosis the same entity? Front Neurol. 2023 Mar 3;14:1132170. doi: 10.3389/fneur.2023.1132170</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018 Feb;17(2):162-73. doi: 10.1016/S1474-4422(17)30470-2. Epub 2017 Dec 21.</mixed-citation><mixed-citation xml:lang="en">Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018 Feb;17(2):162-73. doi: 10.1016/S1474-4422(17)30470-2. Epub 2017 Dec 21.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014 Jul 15;83(3):278-86. doi: 10.1212/WNL.0000000000000560. Epub 2014 May 28.</mixed-citation><mixed-citation xml:lang="en">Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014 Jul 15;83(3):278-86. doi: 10.1212/WNL.0000000000000560. Epub 2014 May 28.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Iacobaeus E, Arrambide G, Amato MP, et al. Aggressive multiple sclerosis (1): toward a definition of the phenotype. Mult Scler. 2020;26:1031- 44. doi: 10.1177/1352458520925369</mixed-citation><mixed-citation xml:lang="en">Iacobaeus E, Arrambide G, Amato MP, et al. Aggressive multiple sclerosis (1): toward a definition of the phenotype. Mult Scler. 2020;26:1031- 44. doi: 10.1177/1352458520925369</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Menon S, Shirani A, Zhao Y, et al. Characterising aggressive multiple sclerosis. J Neurol Neurosurg Psychiatry. 2013 Nov;84(11):1192-8. doi: 10.1136/jnnp-2013-304951. Epub 2013 Jun 6.</mixed-citation><mixed-citation xml:lang="en">Menon S, Shirani A, Zhao Y, et al. Characterising aggressive multiple sclerosis. J Neurol Neurosurg Psychiatry. 2013 Nov;84(11):1192-8. doi: 10.1136/jnnp-2013-304951. Epub 2013 Jun 6.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Ellenberger D, Flachenecker P, Fneish F, et al. Aggressive multiple sclerosis: a matter of measurement and timing. Brain. 2020 Dec 5;143(11):e97. doi: 10.1093/brain/awaa306</mixed-citation><mixed-citation xml:lang="en">Ellenberger D, Flachenecker P, Fneish F, et al. Aggressive multiple sclerosis: a matter of measurement and timing. Brain. 2020 Dec 5;143(11):e97. doi: 10.1093/brain/awaa306</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Gholipour T, Healy B, Baruch NF, et al. Demographic and clinical characteristics of malignant multiple sclerosis. Neurology. 2011 Jun 7;76(23):1996-2001. doi: 10.1212/WNL.0b013e31821e559d</mixed-citation><mixed-citation xml:lang="en">Gholipour T, Healy B, Baruch NF, et al. Demographic and clinical characteristics of malignant multiple sclerosis. Neurology. 2011 Jun 7;76(23):1996-2001. doi: 10.1212/WNL.0b013e31821e559d</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Freedman MS, Rush CA. Severe, Highly Active, or Aggressive Multiple Sclerosis. Continuum (Minneap Minn). 2016 Jun;22(3):761- 84. doi: 10.1212/CON.0000000000000331. Erratum in: Continuum (Minneap Minn). 2018 Jun;24(3, BEHAVIORAL NEUROLOGY AND PSYCHIATRY):967. doi: 10.1212/01.CON.0000534994.77727.73</mixed-citation><mixed-citation xml:lang="en">Freedman MS, Rush CA. Severe, Highly Active, or Aggressive Multiple Sclerosis. Continuum (Minneap Minn). 2016 Jun;22(3):761- 84. doi: 10.1212/CON.0000000000000331. Erratum in: Continuum (Minneap Minn). 2018 Jun;24(3, BEHAVIORAL NEUROLOGY AND PSYCHIATRY):967. doi: 10.1212/01.CON.0000534994.77727.73</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Tintore M, Arrambide G, Otero-Romero S, et al. The long-term outcomes of CIS patients in the Barcelona inception cohort: Looking back to recognize aggressive MS. Mult Scler. 2020 Nov;26(13):1658-69. doi: 10.1177/1352458519877810. Epub 2019 Oct 15.</mixed-citation><mixed-citation xml:lang="en">Tintore M, Arrambide G, Otero-Romero S, et al. The long-term outcomes of CIS patients in the Barcelona inception cohort: Looking back to recognize aggressive MS. Mult Scler. 2020 Nov;26(13):1658-69. doi: 10.1177/1352458519877810. Epub 2019 Oct 15.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Malpas CB, Manouchehrinia A, Sharmin S, et al. Early clinical markers of aggressive multiple sclerosis. Brain. 2020 May 1;143(5):1400- 1413. doi: 10.1093/brain/awaa081</mixed-citation><mixed-citation xml:lang="en">Malpas CB, Manouchehrinia A, Sharmin S, et al. Early clinical markers of aggressive multiple sclerosis. Brain. 2020 May 1;143(5):1400- 1413. doi: 10.1093/brain/awaa081</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Rush CA, MacLean HJ, Freedman MS. Aggressive multiple sclerosis: proposed definition and treatment algorithm. Nat Rev Neurol. 2015 Jul;11(7):379-89. doi: 10.1038/nrneurol.2015.85. Epub 2015 Jun 2.</mixed-citation><mixed-citation xml:lang="en">Rush CA, MacLean HJ, Freedman MS. Aggressive multiple sclerosis: proposed definition and treatment algorithm. Nat Rev Neurol. 2015 Jul;11(7):379-89. doi: 10.1038/nrneurol.2015.85. Epub 2015 Jun 2.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">CHMP. Committee for Medicinal Products for Human Use (CHMP) Assessment Report; 2014. Available at: www.ema.europa.eu (accessed 13.04.2020).</mixed-citation><mixed-citation xml:lang="en">CHMP. Committee for Medicinal Products for Human Use (CHMP) Assessment Report; 2014. Available at: www.ema.europa.eu (accessed 13.04.2020).</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Huisman E, Papadimitropoulou K, Jarrett J, et al. Systematic literature review and network meta-analysis in highly active relapsing-remitting multiple sclerosis and rapidly evolving severe multiple sclerosis. BMJ Open. 2017 Mar 10;7(3):e013430. doi: 10.1136/bmjopen-2016-013430</mixed-citation><mixed-citation xml:lang="en">Huisman E, Papadimitropoulou K, Jarrett J, et al. Systematic literature review and network meta-analysis in highly active relapsing-remitting multiple sclerosis and rapidly evolving severe multiple sclerosis. BMJ Open. 2017 Mar 10;7(3):e013430. doi: 10.1136/bmjopen-2016-013430</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Захарова М.Н. Моноклональные антитела в неврологии: реалии и перспективы. Анналы клинической и экспериментальной неврологии. 2018;12(5S):99-104. doi: 10.25692/ACEN.2018.5.13.</mixed-citation><mixed-citation xml:lang="en">Zakharova MN. Monoclonal antibodies in the treatment of neurological diseases: current state and future development. Annaly klinicheskoj i eksperimental’noj nevrologii = Annals of Сlinical and Experimental Neurology. 2018;12(5S):99- 104. doi: 10.25692/ACEN.2018.5.13 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Diaz C, Zarco LA, Rivera DM. Highly active multiple sclerosis: An update. Mult Scler Relat Disord. 2019 May;30:215-24. doi: 10.1016/j.msard.2019.01.039. Epub 2019 Jan 24.</mixed-citation><mixed-citation xml:lang="en">Diaz C, Zarco LA, Rivera DM. Highly active multiple sclerosis: An update. Mult Scler Relat Disord. 2019 May;30:215-24. doi: 10.1016/j.msard.2019.01.039. Epub 2019 Jan 24.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Хачанова НВ. Высокоактивный рассеянный склероз – возможности выбора терапии моноклональными антителами. Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски. 2019;119(10-2):49-57. doi: 10.17116/jnevro201911910249.</mixed-citation><mixed-citation xml:lang="en">Khachanova NV. Highly active multiple sclerosis: options for monoclonal antibody therapy. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(10-2):49-57. doi: 10.17116/jnevro201911910249 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Шмидт ТЕ, Герасимова АЕ. Агрессивный рассеянный склероз. Неврологический журнал. 2011;16(5):4-10.</mixed-citation><mixed-citation xml:lang="en">Schmidt TE, Gerasimova AE. Aggressive multiple sclerosis. Nevrologicheskiy zhurnal = Neurological Journal. 2011;16(5):4-10 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Fink K. Multiple sclerosis e-registries. Neurodegener Dis Manag. 2016 Dec;6(6s):23- 25. doi: 10.2217/nmt-2016-0051</mixed-citation><mixed-citation xml:lang="en">Fink K. Multiple sclerosis e-registries. Neurodegener Dis Manag. 2016 Dec;6(6s):23- 25. doi: 10.2217/nmt-2016-0051</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Bebo BF Jr, Fox RJ, Lee K, et al. Landscape of MS patient cohorts and registries: Recommendations for maximizing impact. Mult Scler. 2018 Apr;24(5):579-86. doi: 10.1177/1352458517698250. Epub 2017 Mar 1.</mixed-citation><mixed-citation xml:lang="en">Bebo BF Jr, Fox RJ, Lee K, et al. Landscape of MS patient cohorts and registries: Recommendations for maximizing impact. Mult Scler. 2018 Apr;24(5):579-86. doi: 10.1177/1352458517698250. Epub 2017 Mar 1.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Шмидт ТЕ, Яхно НН. Рассеянный склероз: руководство для врачей: [Воспаление. Дегенерация]. 3-е изд. Москва: МЕДпрессинформ; 2012. 271 с.</mixed-citation><mixed-citation xml:lang="en">Schmidt TE, Yakhno NN. Multiple sclerosis: a guide for doctors: [Inflammation. Degeneration]. 3rd ed. Moscow: MEDpressinform; 2012. 271 p. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Гумерова ЗБ, Сафронова ЕВ. Анализ инвалидности вследствие рассеянного склероза в Республике Башкортостан за период 2014–2016 гг. Медико-социальные проблемы инвалидности. 2018;(1):89-91.</mixed-citation><mixed-citation xml:lang="en">Gumerova ZB, Safronova EV. An analysis of disability in consequence of a multiple sclerosis in the Republic of Bashkortostan for a period of 2014–2016 years. Medico-sotsialnye problemy invalidnosty. 2018;(1):89-91 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Кочергин ИА, Абрамова АА., Захарова МН. Опыт создания электронного регистра пациентов с рассеянным склерозом. Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски. 2020;120(7- 2):77-82. doi: 10.17116/jnevro202012007277.</mixed-citation><mixed-citation xml:lang="en">Kochergin IA, Abramova AA, Zakharova MN. Experience in designing an electronic multiple sclerosis registry. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(7-2):77-82. doi: 10.17116/jnevro202012007277 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Kern DM, Cepeda MS. Treatment patterns and comorbid burden of patients newly diagnosed with multiple sclerosis in the United States. BMC Neurol. 2020 Aug 11;20(1):296. doi: 10.1186/s12883-020-01882-2</mixed-citation><mixed-citation xml:lang="en">Kern DM, Cepeda MS. Treatment patterns and comorbid burden of patients newly diagnosed with multiple sclerosis in the United States. BMC Neurol. 2020 Aug 11;20(1):296. doi: 10.1186/s12883-020-01882-2</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Confavreux C, Vukusic S, Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain. 2003 Apr;126(Pt 4): 770-82. doi: 10.1093/brain/awg081</mixed-citation><mixed-citation xml:lang="en">Confavreux C, Vukusic S, Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain. 2003 Apr;126(Pt 4): 770-82. doi: 10.1093/brain/awg081</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Zivadinov R, Cookfair DL, Krupp L, et al. Factors associated with benign multiple sclerosis in the New York State MS Consortium (NYSMSC). BMC Neurol. 2016 Jul 15;16:102. doi: 10.1186/s12883-016-0623-2</mixed-citation><mixed-citation xml:lang="en">Zivadinov R, Cookfair DL, Krupp L, et al. Factors associated with benign multiple sclerosis in the New York State MS Consortium (NYSMSC). BMC Neurol. 2016 Jul 15;16:102. doi: 10.1186/s12883-016-0623-2</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Traboulsee AL, Cornelisse P, Sandberg-Wollheim M, et al. Prognostic factors for long-term outcomes in relapsing-remitting multiple sclerosis. Mult Scler J Exp Transl Clin. 2016 Sep 6;2:2055217316666406. doi: 10.1177/2055217316666406</mixed-citation><mixed-citation xml:lang="en">Traboulsee AL, Cornelisse P, Sandberg-Wollheim M, et al. Prognostic factors for long-term outcomes in relapsing-remitting multiple sclerosis. Mult Scler J Exp Transl Clin. 2016 Sep 6;2:2055217316666406. doi: 10.1177/2055217316666406</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Simone IL, Carrara D, Tortorella C, et al. Course and prognosis in early-onset MS: comparison with adult-onset forms. Neurology. 2002 Dec 24;59(12):1922-8. doi: 10.1212/01.wnl.0000036907.37650.8e</mixed-citation><mixed-citation xml:lang="en">Simone IL, Carrara D, Tortorella C, et al. Course and prognosis in early-onset MS: comparison with adult-onset forms. Neurology. 2002 Dec 24;59(12):1922-8. doi: 10.1212/01.wnl.0000036907.37650.8e</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Ness JM, Chabas D, Sadovnick AD, et al; International Pediatric MS Study Group. Clinical features of children and adolescents with multiple sclerosis. Neurology. 2007 Apr 17;68(16 Suppl 2):S37-45. doi: 10.1212/01.wnl.0000259447.77476.a9</mixed-citation><mixed-citation xml:lang="en">Ness JM, Chabas D, Sadovnick AD, et al; International Pediatric MS Study Group. Clinical features of children and adolescents with multiple sclerosis. Neurology. 2007 Apr 17;68(16 Suppl 2):S37-45. doi: 10.1212/01.wnl.0000259447.77476.a9</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Бойко ОВ, Хорошилова ИИ, Петров СВ и др. Изменения качества жизни пациентов с рассеянным склерозом на фоне курса лечения окрелизумабом. Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски. 2019;119(10-2):120-7. doi: 10.17116/jnevro201911910120.</mixed-citation><mixed-citation xml:lang="en">Boyko OV, Khoroshylova II, Petrov SV, et al. Changes in the quality of life in patients with multiple sclerosis treated with ocrelizumab. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(10-2):120-7. doi: 10.17116/jnevro201911910120 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Бойко АН, Бахтиярова КЗ, Шерман МА и др. Результаты исследования качества жизни у больных с высокоактивным рассеянным склерозом в России. Неврология, нейропсихиатрия, психосоматика. 2022;14(Прил. 1):9- 15. doi: 10.14412/2074-2711-2022-1S-9-15.</mixed-citation><mixed-citation xml:lang="en">Boyko AN, Bakhtiyarova KZ, Sherman MA, et al. Results of a study of the quality of life in patients with highly active multiple sclerosis in Russia. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2022;14(Suppl 1):9-15. doi: 10.14412/2074-2711-2022-1S-9-15 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Ruggieri S, Pontecorvo S, Tortorella C, et al. Induction treatment strategy in multiple sclerosis: a review of past experience and future perspectives. Mult Scler Demyelinat Disord. 2018;3:5-9.</mixed-citation><mixed-citation xml:lang="en">Ruggieri S, Pontecorvo S, Tortorella C, et al. Induction treatment strategy in multiple sclerosis: a review of past experience and future perspectives. Mult Scler Demyelinat Disord. 2018;3:5-9.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
